CardioVascular Resource Group - Consulting Services

HOME | CONTACT

Consulting Services | About the Company | Senior Management

CVrg Consulting Plus™ With over 2,500 pages of cutting-edge analyses already at our fingertips and ongoing rigorous study of 17 CVM disease areas in our Disease Area and Therapy Area reports, CVrg’s experts maintain a decisive advantage over other consulting firms and provides more accurate, forward-looking, and detailed market planning resources than other vendors do.

CVrg delivers:
♦ A credible and unbiased external perspective into client organizations
♦ A comprehensive and rational foundation to support internal decision making
♦ Access to competent experts in the disease area of study
♦ Incisive analyses of complex interconnected factors and market drivers
♦ Incredible value-add by leveraging into 2,500 pages of solid ready-to-go baseline analysis

We specialize in forecasting new product opportunities, evaluating in-license candidates, developing and testing target product profiles, analyzing the competitive landscape, developing accurate worldwide epidemiological models, responding to ad hoc inquiries, and much more.

Patient Population Modeling: To enhance the precision of forecasting for new products, it is imperative to define and quantify the subgroups of patients that the drug will be used in. With our extensive knowledge of the cardiovascular treatment landscape, we understand the key patient characteristics that drive choice of drug use, allowing for rational segmentation that reflects real-world clinical practice. With our custom patient population modeling, we can derive precise, documented and extensively sourced estimates of patient population segments defined based on the key product features and clinical scenarios with a worldwide geographical scope.

Competitive Analysis: A key challenge to competitive analysis lies in defining the pool of competitors and then evaluating a product’s market potential relative to the competition. At CVrg, we take a broad, comprehensive view of competition and provide forward-looking analysis to understand the potential impact of relevant competitors on the adoption of a new product. With full cardiometabolic pipelines on hand, we can quickly focus on the most important competitors.

Target Product Profile Development and Testing: CVrg is well-positioned to build on our expert knowledge of current treatment paradigms to develop and test target product profiles. Our unbiased and analytic approach allows companies to understand how specific product characteristics drive prescriber decision-making, establish key benchmarks and get a realistic view of the potential adoption under specific scenarios.

Opportunity Assessment: CVrg brings a high level of expertise to the evaluation of market opportunities, whether evaluating an in-licensing candidate or potential indications for an internal asset. We have on hand the tools to hit the ground running: detailed epidemiological models, extensive competitive pipelines, relationships with KOLs, and comprehensive understanding of current treatment paradigms, trends, and unmet needs. Our analysts can leverage their expert knowledge of cardiovascular disease to utilize primary and secondary research in creating relevant market segmentation, clarifying the treatment scenarios for new products, and estimating adoption rates. We bring together all of these elements to create a rational market forecast for new products by indication.

About The Company
CardioVascular Resource Group (CVrg) is a privately held consulting firm committed to evaluating the scientific, clinical and commercial potential of cardiovascular biopharmaceuticals and producing the most accurate, insightful, and robust market planning resources possible, with the express purpose of helping our clients succeed in creating winning strategies and making the right business decisions for their new products, brands, franchises, partnerships, and alliances.

Our firm was founded by senior consultants with a vision to add value to clients through more specific expertise in cardiovascular drug markets and broader and deeper market planning resources than our competitors; where their capabilities are attenuated by working in too many non-drug and non-cardiovascular market sectors. Our fundamental belief is that clients are better served by putting all of our firm's analytical efforts and capabilities behind the exclusive study of cardiovascular markets so we can deliver market planning resources with more depth, insight, and precision than would otherwise be possible.

Because of interrelated pathogenesis and common risk factors, the cardiovascular drug market is actually a complex disease continuum with many significant challenges. To unravel this unique landscape CVrg employs highly skilled consultants with a deep understanding of clinical medicine and mechanisms underlying human diseases in cardiovascular therapy areas. Through rigorous and sophisticated methodologies, our firm interprets numerous scientific, clinical, and therapy area developments on an ongoing basis and is adept at evaluating the commercial impact of complicated interconnected market events and how changes in treatment trends, patient populations, and risk factors will weigh into the future marketplace of each disease area we cover.

By empowering talented consultants that continually and exclusively focus on cardiovascular drug markets, and working hand-in-hand with clients to develop the most relevant forward-looking resources possible, we achieve new standards of analytical excellence and deliver the most accurate, insightful, and robust market planning resources available anywhere in this challenging and pivotal healthcare arena.

Senior Management
Stacey McCann (Ph.D.); Senior Partner; Therapy Area Director, Cardiovascular Dr. McCann is a co-founder and senior partner at CVrg. She brings with her a strong analytical aptitude and unique blend of scientific and clinical knowledge and practical commercial experience. She was most recently with the Plan A consulting group as a senior consultant serving a variety of pharmaceutical and biotechnology clients with product market forecasting, market assessments, strategic prioritizations, target product profile development and clinical plan designs, competitive analyses, and epidemiology assessments. She has extensive experience conducting KOL physician primary research and is an expert at integrating analyses from primary and secondary research to determine the future marketplace. She received her Ph.D. in Cancer Biology from Stanford University Medical School and her B.A. in Microbiology from University of California, Santa Barbara. Her coursework and laboratory experience focused on understanding the biology and mechanisms underlying human disease.

Liz Poyner (Ph.D.); Therapy Area Director, CV Risk Factors Dr Poyner is a highly successful Senior Information Analyst with a wealth of expertise in Competitor Intelligence. She brings 15 years of Pharmaceutical Industry experience with her, most recently with GlaxoSmithKline primarily supporting cardiovascular therapeutic areas. Qualified as a Green Belt in Six Sigma, she possesses a proven ability to deliver timely and effective client focused information management solutions, enhanced by exceptional communication skills. She received her BSc and Ph.D. in Chemistry from the University of London. Her research focused on the novel inorganic matrices for the sustained release of L-Dopa, and her postdoctoral research focused on novel liposomes carriers for delivery of antibiotics to the cystic fibrosis lung.

Chung I Choi; Therapy Area Director, Atherosclerosis Ms. Choi has over 10 years of experience consulting to biotechnology and pharmaceutical companies. Her analytical capabilities span a wide range of areas supporting the product development and competitive intelligence functions within companies, such as opportunity assessments, target profile product development, pipeline prioritization, conference coverage, and market forecasting. She excels at conducting primary research with KOLs and is an expert at integrating analyses from primary and secondary research to determine the future marketplace. She received her B.A. from the University of California, Berkeley in Biochemistry and Political Economics.

Michael D. Reynolds; Senior Partner; Director, Client Services Mr. Michael D. Reynolds is a co-founder and senior partner at CVrg. He brings over 20 years of healthcare experience and a deep understanding of the cardiovascular drug industry’s market research needs to develop cutting-edge market planning resources that are relevant to each of our client’s specific needs. His distinguished career includes 12 years of business development resulting in growing a start-up syndicated market research firm into a successful 25 employee consulting group that served many of the industry’s largest pharmaceutical companies. He also draws on several years of direct sales experience to physicians and other healthcare executives and holds a Master of Business Administration from Santa Clara University and a Bachelor of Science in Mechanical Engineering from Washington State University.